Growth Metrics

Coeptis Therapeutics Holdings (COEP) EPS (Weighted Average and Diluted) (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.75 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) fell 1406.72% year-over-year to -$0.75; the TTM value through Sep 2025 reached -$0.75, up 95.29%, while the annual FY2024 figure was -$5.65, 65.88% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.75 in Q3 2025 per COEP's latest filing, up from -$1.28 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.01 in Q3 2021 and bottomed at -$15.8 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$1.61, with a median of -$0.3 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 84.21% in 2022, then plummeted 7574.94% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.25 in 2021, then soared by 83.54% to -$0.21 in 2022, then tumbled by 7574.94% to -$15.8 in 2023, then surged by 65.57% to -$5.44 in 2024, then surged by 86.15% to -$0.75 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.75 in Q3 2025, -$1.28 in Q2 2025, and -$1.11 in Q1 2025.